Company Analysis

Entera Bio Ltd. (ENTX)

Nasdaq: ENTX · Biological Products, (No Diagnostic Substances) · Jerusalem · filing with the SEC since 2015
Grade3.9
◀ Past 3.4● Present 3.5▶ Future 4.5
1 est.

Filings

292 filings since 2017 beside 126 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by May 15, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 37 days after the quarter ended. The proxy statement was last filed Oct 14, 2026.

Filings a yearinsider forms included
2734357938534167
20192020202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 6 times in the last 36 months, the newest Oct 27, 2026.SEC letters: 8 in the last 36 months, the newest May 13, 2026.
Insider forms 126

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 6, 2026 10-Q Quarterly report Sep 30, 2026
Nov 6, 2026 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
Oct 30, 2026 SCHEDULE 13G Large holder notice
Oct 27, 2026 8-K items 5.02, 7.01, 9.01 Officer or director change; Investor disclosure (Regulation FD) · Current report
Oct 14, 2026 DEF 14A Proxy statement
Oct 6, 2026 8-K items 5.02, 7.01, 9.01 Officer or director change; Investor disclosure (Regulation FD) · Current report
Sep 23, 2026 PRE 14A Preliminary proxy statement
Aug 28, 2026 EFFECT Registration effective
Aug 28, 2026 424B3 Shelf offering
Aug 21, 2026 S-3 Shelf registration
Aug 18, 2026 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report
Aug 12, 2026 D Private placement notice
Aug 7, 2026 S-8 Employee stock plan registration
Aug 7, 2026 10-Q Quarterly report Jun 30, 2026
Aug 7, 2026 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
Aug 4, 2026 SCHEDULE 13G Large holder notice
Aug 4, 2026 SCHEDULE 13G Large holder notice
Aug 4, 2026 SCHEDULE 13G Large holder notice
Aug 4, 2026 SCHEDULE 13G Large holder notice
Aug 4, 2026 SCHEDULE 13D Activist holder notice
Jul 28, 2026 8-K items 1.01, 3.02, 5.02, 9.01 Major agreement signed; Shares sold without registration; Officer or director change · Current report Jul 26, 2026
Jul 16, 2026 8-K items 5.02, 5.03, 5.07, 9.01 Officer or director change; Charter, bylaw or fiscal-year change; Shareholder vote · Current report Jul 14, 2026
Jun 3, 2026 DEFA14A Extra proxy material
Jun 3, 2026 ARS Annual report to shareholders
Jun 3, 2026 DEF 14A Proxy statement
May 15, 2026 EFFECT Registration effective
May 15, 2026 424B3 Shelf offering
May 14, 2026 PRE 14A Preliminary proxy statement
May 13, 2026 CORRESP Reply to the SEC
May 12, 2026 UPLOAD SEC comment letter
May 8, 2026 S-3 Shelf registration
May 8, 2026 10-Q Quarterly report Mar 31, 2026
May 8, 2026 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
Apr 3, 2026 8-K items 1.01, 3.02, 9.01 Major agreement signed; Shares sold without registration · Current report Apr 1, 2026
Mar 27, 2026 10-K Annual report Dec 31, 2025
Mar 27, 2026 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
Mar 4, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Feb 9, 2026 8-K items 5.02, 7.01, 9.01 Officer or director change; Investor disclosure (Regulation FD) · Current report Feb 4, 2026
Feb 4, 2026 8-K items 1.01, 5.02, 7.01, 9.01 Major agreement signed; Officer or director change; Investor disclosure (Regulation FD) · Current report Jan 29, 2026
Nov 14, 2025 10-Q Quarterly report Sep 30, 2025
40 of 292 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton ENTX · research, not advice